Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum.
Alzheimer’s disease
amyloid deposition
anxiety
cognition
depressive symptoms
glucose metabolism
gray matter
subjective cognitive decline
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
03
2022
accepted:
30
05
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
Depressive and anxiety symptoms are frequent in Alzheimer's disease and associated with increased risk of developing Alzheimer's disease in older adults. We sought to examine their relationships to Alzheimer's disease biomarkers across the preclinical and clinical stages of the disease. Fifty-six healthy controls, 35 patients with subjective cognitive decline and 56 amyloid-positive cognitively impaired patients on the Alzheimer's continuum completed depression and anxiety questionnaires, neuropsychological tests and neuroimaging assessments. We performed multiple regressions in each group separately to assess within group associations of depressive and anxiety symptoms with either cognition (global cognition and episodic memory) or neuroimaging data (gray matter volume, glucose metabolism and amyloid load). Depressive symptoms, but not anxiety, were higher in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer's continuum compared to healthy controls. Greater depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism, and to better awareness of cognitive difficulties, in cognitively impaired patients on the Alzheimer's continuum. In contrast, anxiety symptoms were not associated with brain integrity in any group. These data show that more depressive symptoms are associated with greater Alzheimer's disease biomarkers in subjective cognitive decline patients, while they reflect better cognitive deficit awareness in cognitively impaired patients on the Alzheimer's continuum. Our findings highlight the relevance of assessing and treating depressive symptoms in the preclinical stages of Alzheimer's disease.
Sections du résumé
Background
UNASSIGNED
Depressive and anxiety symptoms are frequent in Alzheimer's disease and associated with increased risk of developing Alzheimer's disease in older adults. We sought to examine their relationships to Alzheimer's disease biomarkers across the preclinical and clinical stages of the disease.
Method
UNASSIGNED
Fifty-six healthy controls, 35 patients with subjective cognitive decline and 56 amyloid-positive cognitively impaired patients on the Alzheimer's continuum completed depression and anxiety questionnaires, neuropsychological tests and neuroimaging assessments. We performed multiple regressions in each group separately to assess within group associations of depressive and anxiety symptoms with either cognition (global cognition and episodic memory) or neuroimaging data (gray matter volume, glucose metabolism and amyloid load).
Results
UNASSIGNED
Depressive symptoms, but not anxiety, were higher in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer's continuum compared to healthy controls. Greater depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism, and to better awareness of cognitive difficulties, in cognitively impaired patients on the Alzheimer's continuum. In contrast, anxiety symptoms were not associated with brain integrity in any group.
Conclusion
UNASSIGNED
These data show that more depressive symptoms are associated with greater Alzheimer's disease biomarkers in subjective cognitive decline patients, while they reflect better cognitive deficit awareness in cognitively impaired patients on the Alzheimer's continuum. Our findings highlight the relevance of assessing and treating depressive symptoms in the preclinical stages of Alzheimer's disease.
Identifiants
pubmed: 35795235
doi: 10.3389/fnagi.2022.899158
pmc: PMC9251580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
899158Informations de copyright
Copyright © 2022 Moulinet, Touron, Mézenge, Dautricourt, De La Sayette, Vivien, Marchant, Poisnel and Chételat.
Déclaration de conflit d'intérêts
GP was a member of the DSMB of the Age-well trial for the Inserm Partner (not paid). GC was Member of the External Advisory Board (EAB) of the Lifebrain H2020 European project and of the Operational Committee of the Foundation Plan Alzheimer (personal fees) and of the Imaging Scientific Advisory Groups of European Prediction of Alzheimer’s Disease (EPAD) Consortium, EU (not paid). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hum Brain Mapp. 2016 Jan;37(1):35-53
pubmed: 26441321
Psychiatry Clin Neurosci. 2005 Dec;59(6):697-704
pubmed: 16401246
Alzheimers Dement (Amst). 2016 Dec 18;5:23-34
pubmed: 28054025
J Cereb Blood Flow Metab. 1992 Jul;12(4):571-83
pubmed: 1618936
Neurology. 2017 Nov 14;89(20):2031-2038
pubmed: 29046362
Ann Neurol. 2015 Sep;78(3):477-86
pubmed: 26085009
Am J Psychiatry. 2014 May;171(5):572-81
pubmed: 24700290
Acta Neurol Scand. 2006 Jan;113(1):40-5
pubmed: 16367898
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
Front Aging Neurosci. 2021 Aug 03;13:697234
pubmed: 34413767
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Int Psychogeriatr. 1996;8 Suppl 3:497-500
pubmed: 9154615
Arch Neurol. 2005 Jul;62(7):1160-3; discussion 1167
pubmed: 16009779
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2016 Nov 19;55(2):551-558
pubmed: 27802220
Int J Geriatr Psychiatry. 2015 Jul;30(7):677-85
pubmed: 25345806
Int Psychogeriatr. 2018 Feb;30(2):245-251
pubmed: 29198244
Arq Neuropsiquiatr. 2015 Jul;73(7):553-60
pubmed: 26200048
Cereb Cortex. 2019 May 1;29(5):1889-1899
pubmed: 29668866
Alzheimers Dement. 2017 May;13(5):550-560
pubmed: 27693187
Int J Geriatr Psychiatry. 2010 Aug;25(8):780-8
pubmed: 19946864
J Geriatr Psychiatry Neurol. 2016 May;29(3):149-59
pubmed: 26400248
Brain. 2008 Sep;131(Pt 9):2455-63
pubmed: 18669506
Brain. 2008 Jan;131(Pt 1):60-71
pubmed: 18063588
Arch Neurol. 2012 Feb;69(2):223-9
pubmed: 22332189
J Alzheimers Dis. 2017;60(2):483-493
pubmed: 28869463
Curr Alzheimer Res. 2010 Sep;7(6):517-26
pubmed: 20455862
Clin Neuropsychol. 2022 Jan;36(1):138-164
pubmed: 32544371
J Alzheimers Dis Rep. 2021 Mar 08;5(1):171-177
pubmed: 33981954
Neurology. 2015 Jul 7;85(1):56-62
pubmed: 26048028
Arch Clin Neuropsychol. 2005 Mar;20(2):271-6
pubmed: 15708735
Hum Brain Mapp. 2016 Dec;37(12):4234-4247
pubmed: 27412866
Br J Psychiatry. 2006 May;188:460-4
pubmed: 16648533
Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):716-24
pubmed: 25631614
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Aust N Z J Psychiatry. 2015 Jan;49(1):36-46
pubmed: 25414381
Psychol Med. 2004 Aug;34(6):1129-35
pubmed: 15554582
J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):930-5
pubmed: 24421287
Front Psychiatry. 2021 Mar 31;12:631518
pubmed: 33868048
J Affect Disord. 2020 Sep 1;274:262-268
pubmed: 32469814
J Neurosci. 2008 Jun 11;28(24):6174-81
pubmed: 18550759
Neurobiol Aging. 2020 Oct;94:250-264
pubmed: 32679396
J Neurosci. 2012 Nov 14;32(46):16265-73
pubmed: 23152610
Neuroimage Clin. 2017 May 25;15:408-414
pubmed: 28616381
Acta Neurol Scand. 2013 May;127(5):344-50
pubmed: 23215819
J Alzheimers Dis. 2010;22(3):993-1003
pubmed: 20858977
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S151-9
pubmed: 26402082
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Int J Geriatr Psychiatry. 2007 Oct;22(10):1031-6
pubmed: 17380488
J Neuropsychiatry Clin Neurosci. 2006 Fall;18(4):521-8
pubmed: 17135378
J Psychiatry Neurosci. 2008 May;33(3):218-26
pubmed: 18592038
Ann Neurol. 2020 Feb;87(2):267-280
pubmed: 31750553
J Geriatr Psychiatry Neurol. 2015 Mar;28(1):40-8
pubmed: 25080472
Br J Radiol. 2014 Oct;87(1042):20140150
pubmed: 25061711
J Neuropsychiatry Clin Neurosci. 2009 Summer;21(3):259-65
pubmed: 19776304
Int Psychogeriatr. 2013 Aug;25(8):1307-15
pubmed: 23693133
J Neurosci. 2015 Jul 22;35(29):10402-11
pubmed: 26203136
JAMA Netw Open. 2020 Dec 1;3(12):e2027472
pubmed: 33263761
Psychiatry Res. 2011 Oct 31;194(1):7-13
pubmed: 21920712
Alzheimers Res Ther. 2019 Jul 8;11(1):61
pubmed: 31286994
Transl Psychiatry. 2019 Mar 28;9(1):123
pubmed: 30923322
J Alzheimers Dis. 2010;21(2):627-39
pubmed: 20555138
Neurosci Biobehav Rev. 2019 Dec;107:346-359
pubmed: 31525387
Acta Psychiatr Scand. 2015 Feb;131(2):139-47
pubmed: 25346330
J Alzheimers Dis. 2015;49(2):387-98
pubmed: 26484900
J Alzheimers Dis. 2015;46(1):63-73
pubmed: 25697700
Alzheimers Dement. 2016 Apr;12(4):399-406
pubmed: 26549599
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):449-55
pubmed: 24133289
Front Aging Neurosci. 2020 May 12;12:107
pubmed: 32477094
Neuropsychologia. 2012 Oct;50(12):2880-2886
pubmed: 22940426
Hum Brain Mapp. 2006 Jul;27(7):588-97
pubmed: 16247783
Dement Geriatr Cogn Disord. 2014;38(3-4):153-60
pubmed: 24732302
Lancet Neurol. 2020 Mar;19(3):271-278
pubmed: 31958406
Mol Neurodegener. 2021 Jun 7;16(1):38
pubmed: 34099005
Neurosci Lett. 2013 Aug 26;548:15-20
pubmed: 23727389
Front Aging Neurosci. 2014 Nov 07;6:306
pubmed: 25426066